Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

December 28, 2017

Primary Completion Date

August 23, 2021

Study Completion Date

April 28, 2023

Conditions
Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytomaOligodendroglioma, ChildhoodAnaplastic OligodendrogliomaGlioblastomaPilocytic AstrocytomaGiant Cell AstrocytomaPleomorphic XanthoastrocytomaAnaplastic Pleomorphic XanthoastrocytomaAngiocentric GliomaChordoid Glioma of Third VentricleGangliocytomaGangliogliomaAnaplastic GangliogliomaDysplastic Gangliocytoma of CerebrellumDesmoplastic Infantile Astrocytoma and GangliogliomaPapillary Glioneuronal TumorRosette-forming Glioneurona TumorCentral NeurocytomaExtraventricular NeurocytomaCerebellar Iponeurocytoma
Interventions
DRUG

Dabrafenib

Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)

DRUG

trametinib

"Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)"

DRUG

Carboplatin

"Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle."

DRUG

Vincristine

"Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing."

Trial Locations (57)

2130

Novartis Investigative Site, Randwick

3052

Novartis Investigative Site, Parkville

3584

Novartis Investigative Site, Utrecht

8032

Novartis Investigative Site, Zurich

10126

Novartis Investigative Site, Torino

13353

Novartis Investigative Site, Berlin

16147

Novartis Investigative Site, Genova

17176

Novartis Investigative Site, Stockholm

20010

Childrens National Hospital, Washington D.C.

20133

Novartis Investigative Site, Milan

20246

Novartis Investigative Site, Hamburg

21287

Johns Hopkins University IDS Pharmacy John Hopkins Hospital, Baltimore

28009

Novartis Investigative Site, Madrid

31059

Novartis Investigative Site, Toulouse

33155

Nicklaus Childrens Hospital, Miami

33521

Novartis Investigative Site, Tampere

37075

Novartis Investigative Site, Göttingen

38105

St Jude Children's Research Hospital, Memphis

45147

Novartis Investigative Site, Essen

46026

Novartis Investigative Site, Valencia

49202

Novartis Investigative Site, Petah Tikva

50139

Novartis Investigative Site, Florence

50937

Novartis Investigative Site, Cologne

52621

Novartis Investigative Site, Tel Litwinsky

59020

Novartis Investigative Site, Lille

60611

Ann and Robert H Lurie Childrens Hospital of Chicago ., Chicago

63110

Washington University School of Medicine SC, St Louis

67000

Novartis Investigative Site, Strasbourg

69120

Novartis Investigative Site, Heidelberg

69373

Novartis Investigative Site, Lyon

75231

Novartis Investigative Site, Paris

77030

Texas Children s Hospital Baylor College of Medicine, Houston

86179

Novartis Investigative Site, Augsburg

92868

Children's Hospital of Orange County, Orange

94800

Novartis Investigative Site, Villejuif

117198

Novartis Investigative Site, Moscow

46202-2810

Indiana University School of Medicine ., Indianapolis

45229-3039

Cincinnati Childrens Hospital Medical Center Cancer & Blood Disease Inst., Cincinnati

C1428AQK

Novartis Investigative Site, CABA

BE-B-1200

Novartis Investigative Site, Brussels

14784 400

Novartis Investigative Site, Barretos

04829-310

Novartis Investigative Site, São Paulo

08270-070

Novartis Investigative Site, São Paulo

V6H 3V4

Novartis Investigative Site, Vancouver

M5G 1X8

Novartis Investigative Site, Toronto

H3T 1C5

Novartis Investigative Site, Montreal

613 00

Novartis Investigative Site, Brno

150 06

Novartis Investigative Site, Prague

2100 O

Novartis Investigative Site, Copenhagen

00165

Novartis Investigative Site, Roma

812-8582

Novartis Investigative Site, Fukuoka

157-8535

Novartis Investigative Site, Setagaya-ku

534-0021

Novartis Investigative Site, Osaka

08035

Novartis Investigative Site, Barcelona

LS1 3EX

Novartis Investigative Site, Leeds

L12 2AP

Novartis Investigative Site, Liverpool

WC1N 3JH

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY